Christopher Andrew, MD
Neurology · Joplin, MONPI 1184660995
Payments from drug & device makers
Across 287 payments — averaging $267.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$73K
- Teva Pharmaceuticals USA, Inc.$678
- Eisai Inc.$523
- EMD Serono, Inc.$399
- AbbVie$383
- Otsuka America Pharmaceutical, Inc.$298
- plus $1K from 28 others
What the payments were for
- Consulting fees$11,81915%
- Speaking & faculty fees$53,26769%
- Travel & lodging$5,4247%
- Food & beverage$6,1858%
- Education$1590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 129 | $73,114 |
| Teva Pharmaceuticals USA, Inc. | 30 | $678 |
| Eisai Inc. | 21 | $523 |
| EMD Serono, Inc. | 8 | $399 |
| AbbVie(2 entities) | 18 | $383 |
| Otsuka America Pharmaceutical, Inc. | 11 | $298 |
| UCB, Inc. | 11 | $199 |
| Novartis | 6 | $148 |
| Argenx US, Inc. | 3 | $132 |
| Sanofi | 6 | $118 |
| Bioventus LLC | 1 | $99 |
| Pfizer | 6 | $94 |
| Bristol Myers Squibb | 5 | $75 |
| Jazz Pharmaceuticals Inc. | 3 | $57 |
| Lilly USA, LLC | 3 | $55 |
| Lundbeck LLC | 3 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Novo Nordisk | 3 | $41 |
| Acadia Pharmaceuticals Inc | 1 | $34 |
| CSL Behring | 2 | $32 |
| Sobi, Inc | 1 | $30 |
| ANI Pharmaceuticals, Inc. | 2 | $29 |
| SK Life Science, Inc. | 1 | $26 |
| Averitas Pharma Inc. | 1 | $24 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| AstraZeneca | 1 | $22 |
| Acorda Therapeutics, Inc | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Kedrion Biopharma, Inc. | 1 | $18 |
| Grifols USA, LLC | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Cycle Pharmaceuticals Inc | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,854 in reported general payments places this provider in the 80th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 36 | $437,647 |
| RebifInterferon Beta-1a/Albumin | 14 | $169,175 |
| TecfideraDimethyl Fumarate | 11 | $97,006 |
| Teriflunomide | 74 | $90,878 |
| IngrezzaValbenazine Tosylate | 12 | $88,883 |
| FingolimodFingolimod Hcl | 12 | $86,621 |
| Aimovig AutoinjectorErenumab-Aooe | 95 | $77,162 |
| CopaxoneGlatiramer Acetate | 11 | $66,166 |
| QuliptaAtogepant | 46 | $51,286 |
| GlatopaGlatiramer Acetate | 27 | $43,381 |
| Nurtec OdtRimegepant Sulfate | 31 | $42,042 |
| Emgality PenGalcanezumab-Gnlm | 43 | $34,532 |
| RytaryCarbidopa/Levodopa | 13 | $26,574 |
| Lacosamide | 191 | $24,235 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 16 | $23,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $17 | $437,64736 claims |
| EMD Serono, Inc.Rebif | $399 | $169,17514 claims |
| BiogenTecfidera | $73,114 | $97,00611 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $678 | $66,16611 claims |
| PfizerNurtec Odt, Eliquis, Dilantin | $94 | $55,22073 claims |
| AbbVieQulipta | $383 | $51,28646 claims |
| Eisai Inc.Dayvigo | $523 | $3,49011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 381 neurology providers in Missouri.
Other neurology in Joplin
- Gulshan UppalJoplin$200K
- Randall BatemanSaint Louis$92.3M
- David HoltzmanSaint Louis$25.2M
- Robert NaismithSaint Louis$13.8M
- Eric McDadeSaint Louis$9.6M
- Robert BucelliSaint Louis$8.5M
- Barbara SniderSaint Louis$7M
- Curtis SchreiberBolivar$6.4M
- Gregory WuSaint Louis$5.7M
- Siddharth KaulBridgeton$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.